Aspirin interruption before neurosurgical interventions:A controversial problem  

作　　者：Alexander Kulikov Anton Konovalov Pier Paolo Pugnaloni Federico Bilotta 

机构地区：[1]Department of Anesthesiology,Burdenko National Medical Research Center of Neurosurgery,Moscow 125047,Russia [2]Department of Vascular Neurosurgery,Burdenko National Medical Research Center of Neurosurgery,Moscow 125047,Russia [3]Department of Anesthesiology,Critical Care and Pain Medicine,University of Rome“Sapienza”,Rome 00161,Italy

出　　处：《World Journal of Cardiology》2024年第4期191-198,共8页世界心脏病学杂志（英文版）（电子版）

摘　　要：Aspirin is widely used for primary or secondary prevention of ischemic events.At the same time,chronic aspirin consumption can affect blood clot formation during surgical intervention and increase intraoperative blood loss.This is especially important for high-risk surgery,including neurosurgery.Current European Society of Cardiology guidelines recommend aspirin interruption for at least 7 d before neurosurgical intervention,but this suggestion is not supported by clinical evidence.This narrative review presents evidence that challenges the necessity for aspirin interruption in neurosurgical patients,describes options for aspirin effect monitoring and the clinical implication of these methods,and summarizes current clinical data on bleeding risk associated with chronic aspirin therapy in neurosurgical patients,including brain tumor surgery,cerebrovascular procedures,and spinal surgery.

关 键 词：ASPIRIN NEUROSURGERY Postoperative complications Bleeding risk Brain tumor surgery Cerebrovascular surgery Spinal surgery 

分 类 号：R654.2[医药卫生—外科学]